DiaMedica’s DM199 Stroke Drug

(1:44)

DiaMedica DM199 AIS Mechanism

(3:57)

KOL Webinar on DM199 for the Treatment of Acute Ischemic Stroke

(1:27:11)

The First New Ischemic Stroke Treatment in 25 years by DiaMedica Therapeutics

(12:34)

DiaMedica Therapeutics (DMA) targeting stroke and diabetic kidney disease

(35)

Cramer: This biotech stock could be worth over $100 billion on an FDA approval

(5:19)

$DMAC stock research, Should I buy DiaMedica Therapeutics?

(4:48)

Is XORTX Greatly Undervalued Compared to its Peers? Company Overview (CSE: XRX)

(18:3)

XORTX Therapeutics (CSE:XRX | OTCQB:XRTXF | FRA:ANU1) CEO Dr. Allen Davidoff interview

(14:35)

CEO of Diffusion Pharmaceuticals Shares the Progress of Current and Future Oxygenation Trials

(27:19)

DiaMedica Inc. (TSXV: DMA) Announces a non-brokered private placement

(1:45)

Delcath Systems: Filtering Through Its Past \u0026 Future

(47:49)

Rising Problems \u0026 Innovations in the Treatment of Stroke - [Health Matters]

(3:)

DMAC stock – Best stock to buy now +170% Potential Upside #shorts

(32)

DMAC Price and Volume Analysis by 650 Day Look Back DMAC Stock Analysis for DiaMedica Therapeutics S

(12:24)

DMAC Price and Volume Analysis by 650 Day Look Back DMAC Stock Analysis for DiaMedica Therapeutics S

(12:19)

Dyadic Presents at H.C. Wainwright 23rd Annual Global Investment Conference

(22:57)

IPO Review Xilio Therapeutics XLO Stock Going Public October 22 2021

(4:8)